Safety and efficacy of nirmatrelvir and ritonavir in kidney transplant recipients with COVID-19
Clinical Nephrology · 01.08.2026 · 106 (2) · 96-109
DOI: 10.5414/cn111815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nephrology, erschienen am 01.08.2026. Verfasst von Yadi Wang und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ritonavir, Kidney Transplantation, COVID-19, COVID-19 Drug Treatment.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Wang, Y., Zhang, K., Liu, L., Tang, M., Tang, M., Shen, L., Peng, Q., Hu, B., & Rao, Z. (2026). Safety and efficacy of nirmatrelvir and ritonavir in kidney transplant recipients with COVID-19. Clinical Nephrology, 106(2), 96-109. https://doi.org/10.5414/cn111815
Vancouver
Wang Y, Zhang K, Liu L, Tang M, Tang M, Shen L, et al. Safety and efficacy of nirmatrelvir and ritonavir in kidney transplant recipients with COVID-19. Clinical Nephrology. 2026;106(2):96-109. doi:10.5414/cn111815
BibTeX
@article{Wang2026,
author = {Wang, Yadi and Zhang, Keqin and Liu, Ling and Tang, Maozhi and Tang, Ming and Shen, Linguo and Peng, Qiongyao and Hu, Bangqin and Rao, Zhengsheng},
title = {Safety and efficacy of nirmatrelvir and ritonavir in kidney transplant recipients with COVID-19},
journal = {Clinical Nephrology},
year = {2026},
volume = {106},
number = {2},
pages = {96--109},
doi = {10.5414/cn111815}
}
EUVIMED